Dipeptidyl peptidase-4 inhibitor anagliptin facilitates restoration of dextran sulfate sodium-induced colitis

References

• Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998;115:182–205.
   PubMed Web of Science ®Google Scholar
• Shih DQ, Targan SR. Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol 2008;14:390–400.
   PubMed Web of Science ®Google Scholar
• Chevaux JB, Peyrin-Biroulet L, Sparrow MP. Optimizing thiopurine therapy in inflammatory bowel disease. Inflamm Bowel Dis 2010;17:1428–35.
   PubMed Web of Science ®Google Scholar
• Hayashi Y. Metabolic impact of glucagon deficiency. Diabetes Obes Metab 2011;13:151–7.
   PubMed Web of Science ®Google Scholar
• Brubaker PL, Crivici A, Izzo A, Ehrlich P, Tsai CH, Drucker DJ. Circulating and tissue forms of the intestinal growth factor, glucagon-like peptide-2. Endocrinology 1997;138:4837–43.
   PubMed Web of Science ®Google Scholar
• Brubaker PL, Izzo A, Hill M, Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol 1997;272:E1050–8.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996;93:7911–16.
   PubMed Web of Science ®Google Scholar
• Yazbeck R, Abbott CA, Howarth GS. The use of GLP-2 and related growth factors in intestinal diseases. Curr Opin Investig Drugs 2010;11:440–6.
   PubMedGoogle Scholar
• Ahren B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab 2007;21:517–33.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 2007;30:1335–43.
   PubMed Web of Science ®Google Scholar
• Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci 2009;30:600–7.
   PubMed Web of Science ®Google Scholar
• Yazbeck R, Howarth GS, Geier MS, Demuth HU, Abbott CA. Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice. Front Biosci 2008;13:6850–8.
   PubMedGoogle Scholar
• Bank U, Heimburg A, Helmuth M, Stefin S, Lendeckel U, Reinhold D, et al. Triggering endogenous immunosuppressive mechanisms by combined targeting of dipeptidyl peptidase IV (DPIV/CD26) and aminopeptidase N (APN/CD13)–a novel approach for the treatment of inflammatory bowel disease. Int Immunopharmacol 2006;6:1925–34.
   PubMed Web of Science ®Google Scholar
• Yazbeck R, Sulda ML, Howarth GS, Bleich A, Raber K, von Horsten S, et al. Dipeptidyl peptidase expression during experimental colitis in mice. Inflamm Bowel Dis 2010;16:1340–51.
   PubMed Web of Science ®Google Scholar
• Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993;69:238–49.
   PubMed Web of Science ®Google Scholar
• Bauer C, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 2010;59:1192–9.
   PubMed Web of Science ®Google Scholar
• Joly F, Mayeur C, Messing B, Lavergne-Slove A, Cazals- Hatem D, Noordine ML, et al. Morphological adaptation with preserved proliferation/transporter content in the colon of patients with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2009;297:G116–23.
   PubMed Web of Science ®Google Scholar
• Kirino Y, Sato Y, Kamimoto T, Kawazoe K, Minakuchi K. Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic rats. Am J Physiol Endocrinol Metab 2010;300:E372–9.
   PubMed Web of Science ®Google Scholar
• Lankas GR, Leiting B, Roy RS, Eiermann GJ, Beconi MG, Biftu T, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005;54:2988–94.
   PubMed Web of Science ®Google Scholar
• Kato N, Oka M, Murase T, Yoshida M, Sakairi M, Yamashita S, et al. Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methyl pyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg Med Chem 2011;19:7221–7.
   PubMed Web of Science ®Google Scholar
• Okawada M, Holst JJ, Teitelbaum DH. Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndrome. Surgery 2011;150:217–23.
   PubMed Web of Science ®Google Scholar
• Ban H, Bamba S, Imaeda H, Inatomi O, Kobori A, Sasaki M, et al. The DPP-IV inhibitor ER-319711 has a proliferative effect on the colonic epithelium and a minimal effect in the amelioration of colitis. Oncol Rep 2011;25:1699–703.
   PubMed Web of Science ®Google Scholar
• Tsai CH, Hill M, Drucker DJ. Biological determinants of intestinotrophic properties of GLP-2 in vivo. Am J Physiol 1997;272:G662–8.
   Web of Science ®Google Scholar
• Dube PE, Forse CL, Bahrami J, Brubaker PL. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology 2006;131:589–605.
   PubMed Web of Science ®Google Scholar
• Rowland KJ, Trivedi S, Lee D, Wan K, Kulkarni RN, Holzenberger M, et al. Loss of glucagon-like peptide-2- induced proliferation following intestinal epithelial insulin- like growth factor-1-receptor deletion. Gastroenterology 2011;141:2166–75; e7.
   PubMed Web of Science ®Google Scholar
• Howarth GS, Xian CJ, Read LC. Insulin-like growth factor-I partially attenuates colonic damage in rats with experimental colitis induced by oral dextran sulphate sodium. Scand J Gastroenterol 1998;33:180–90.
   PubMed Web of Science ®Google Scholar
• Orskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept 2005;124:105–12.
   PubMed Web of Science ®Google Scholar
• Egger B, Procaccino F, Sarosi I, Tolmos J, Buchler MW, Eysselein VE. Keratinocyte growth factor ameliorates dextran sodium sulfate colitis in mice. Dig Dis Sci 1999;44:836–44.
   PubMed Web of Science ®Google Scholar
• Miceli R, Hubert M, Santiago G, Yao DL, Coleman TA, Huddleston KA, et al. Efficacy of keratinocyte growth factor-2 in dextran sulfate sodium-induced murine colitis. J Pharmacol Exp Ther 1999;290:464–71.
   PubMed Web of Science ®Google Scholar
• Ansorge S, Bank U, Heimburg A, Helmuth M, Koch G, Tadje J, et al. Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med 2009;47:253–61.
   PubMed Web of Science ®Google Scholar